A B2B certification and licensing program that provides private psychiatric practices with a manualized clinical protocol for psychedelic-assisted therapy. The service includes training, adherence tracking tools, and standardized session roadmaps for integrating psilocybin or MDMA into clinical care.
The SWOT analysis reveals a high-value B2B positioning that leverages the critical link between psychedelic efficacy and structured psychological support. While the model cleverly avoids the legal risks of drug distribution, its success depends on the ability to standardize high-risk clinical encounters and navigate a fragmented regulatory landscape.
Strengths4
Weaknesses3
Opportunities3
Threats3
It is essential to balance the internal strength of a manualized evidence-based protocol against the external threat of clinical risks and 'bad trips'. · Generated 2026-09-22 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated